SCHEMBL26243763

SCHEMBL26243763

CCC(=O)N(C)CCn1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)ncnc21

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 19/20 0.78
LCK P06239 10/20 0.78
EGFR P00533 8/20 0.78
ITK Q08881 8/20 0.78
JAK3 P52333 4/20 0.78
NUDT14 O95848 1/20 0.59
NUDT5 Q9UKK9 1/20 0.59
FYN P06241 4/20 0.53
LYN P07948 4/20 0.53
SRC P12931 4/20 0.53
FLT3 P36888 4/20 0.53
PTK6 Q13882 4/20 0.53
HCK P08631 3/20 0.53
FGR P09769 3/20 0.53
MAP2K1 Q02750 3/20 0.53
BRAF P15056 3/20 0.53
YES1 P07947 2/20 0.53
BLK P51451 2/20 0.53
BMX P51813 2/20 0.53
MAP2K5 Q13163 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14617775 0.91 BTK (0.80) BTKLCKEGFRITKJAK3
SCHEMBL14617768 0.91 BTK (0.80) BTKLCKEGFRITKJAK3
SCHEMBL17090645 0.91 BTK (0.80) BTKLCKEGFRITKJAK3
SCHEMBL14643775 0.89 BTK (0.78) BTKLCKEGFRITKJAK3
SCHEMBL410081 0.89 BTK (0.82) BTKLCKEGFRITKJAK3
SCHEMBL22300431 0.88 BTK (0.71) BTKLCKEGFRITKJAK3
SCHEMBL18476811 0.88 BTK (0.78) BTKLCKEGFRITKJAK3
SCHEMBL409516 0.88 BTK (0.75) BTKLCKEGFRITKJAK3
SCHEMBL409254 0.88 BTK (1.00) BTKLCKEGFRITKJAK3
SCHEMBL29663809 0.88 BTK (1.00) BTKLCKEGFRITKJAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230293532-A1 USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) PHARMACYCLICS LLC (US) 2023-09-21 US disclosed
US-9862722-B2 Inhibitors of Bruton's tyrosine kinase PHARMACYCLICS LLC (US) 2018-01-09 US disclosed
US-20150329550-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE PHARMACYCLICS LLC (US) 2015-11-19 US disclosed
US-9138436-B2 Inhibitors of Bruton's tyrosine kinase PHARMACYCLICS LLC (US) 2015-09-22 US disclosed
US-20130018032-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE PHARMACYCLICS, INC. (US) 2013-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150329550-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE ABL1, BTK, ABL2 BTK 2/4885LCK 19/4885EGFR 947/4885
US-20130018032-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE ABL1, BTK, ABL2 BTK 2/4885LCK 19/4885EGFR 947/4885
US-20230293532-A1 USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) BTK, LYN, SYK BTK 1/4885LCK 5/4885EGFR 985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.